Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study.
OBJECTIVE
This study was undertaken to investigate the efficacy and safety of botulinum-A toxin (BTX-A) treatment for non-neurogenic detrusor overactivity incontinence.


METHODS
This prospective nonrandomized ongoing study was performed in a tertiary referral urogynecology department. In 26 women with urge incontinence and urodynamically demonstrated detrusor overactivity incontinence resistant to conventional treatment 100 units of BTX-A were injected into the detrusor muscle at 30 sites. Clinical and urodynamic evaluations and a quality of life assessment were performed at baseline and 4, 12, and 36 weeks after BTX-A treatment.


RESULTS
Of 26 women, 14 were dry after 4 weeks, 13 of 20 women after 12 weeks, and 3 of 5 women after 36 weeks. Two women failed to respond. Two women were on self-catheterization temporarily. There were no other complications besides 9 urinary tract infections within the 51 follow-up visits.


CONCLUSIONS
BTX-A treatment seems to be a safe and efficacious new treatment option for patients with detrusor overactivity incontinence.
Werner
Matthias
M
Department of Obstetrics and Gynecology, Cantonal Hospital Lucerne, Switzerland.
Schmid
Daniel Max
DM
Schüssler
Bernhard
B
D000368:Aged; D000369:Aged, 80 and over; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D011788:Quality of Life; D019233:Retreatment; D016896:Treatment Outcome; D001745:Urinary Bladder Diseases / Q000150:complications* / Q000188:drug therapy*; D014549:Urinary Incontinence / Q000209:etiology* / Q000503:physiopathology; D014563:Urodynamics
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A